Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB2102 + penpulimab + chemotherapy
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
TQB2102 + penpulimab + chemotherapy is a combination therapeutic regimen being investigated for the treatment of HER2-positive gastroesophageal adenocarcinoma. The regimen integrates three distinct anti-tumor strategies: TQB2102, a next-generation antibody-drug conjugate (ADC) that bi-specifically targets the ECD2 and ECD4 domains of the Human Epidermal Growth Factor Receptor 2 (HER2) to enhance receptor internalization and deliver a cytotoxic payload; penpulimab (AK105), a humanized IgG1 monoclonal antibody that inhibits the Programmed Cell Death Protein 1 (PD-1) receptor to reactivate the immune system against tumor cells; and conventional cytotoxic chemotherapy. Developed by Chia Tai Tianqing Pharmaceutical Group in collaboration with Akeso (for penpulimab), this combination is currently in Phase II clinical development, aiming to improve outcomes in patients with advanced, recurrent, or metastatic HER2-positive gastric and gastroesophageal junction cancers by leveraging synergistic targeted, immunological, and cytotoxic mechanisms.
- Brand names
- Anniso
- Other names
- TQB2102 + AK105 + chemotherapyTQB2102 plus penpulimab plus chemotherapyTQB-2102 plus penpulimab plus chemotherapyTQB 2102 plus penpulimab plus chemotherapy
02
Targets
DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on TQB2102 + penpulimab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB2102 + penpulimab + chemotherapy.